Kyprolis carfilzomib: Phase I/IIb data

Data from 40 patients in the open-label, U.S. Phase I/IIb PCYC-1119 trial showed that once-daily 560 and 840 mg Imbruvica plus 20/27 and 20/36 mg/m 2 Kyprolis carfilzomib with and without dexamethasone led to no dose-limiting toxicities (DLTs). In 36 patients evaluable for efficacy, the ORR was 58% and the clinical benefit rate (CBR) was 67%. In patients receiving 840 mg Imbruvica plus 20/36 mg/m 2 Kyprolis with dexamethasone, the CBR was 77% and the ORR was 65%, including 3 very good partial responses and 1 stringent complete response. Next month, data will be presented at the American Society of Hematology meeting in Orlando. ...